CO2020000260A2 - Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide - Google Patents

Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide

Info

Publication number
CO2020000260A2
CO2020000260A2 CONC2020/0000260A CO2020000260A CO2020000260A2 CO 2020000260 A2 CO2020000260 A2 CO 2020000260A2 CO 2020000260 A CO2020000260 A CO 2020000260A CO 2020000260 A2 CO2020000260 A2 CO 2020000260A2
Authority
CO
Colombia
Prior art keywords
amyloid deposition
treatment
chimeric antibodies
antibody
deposition diseases
Prior art date
Application number
CONC2020/0000260A
Other languages
English (en)
Inventor
Tarran Jones
Alison Levy
Siobhan O'brien
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of CO2020000260A2 publication Critical patent/CO2020000260A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)

Abstract

Un anticuerpo humano de ratón quimérico para el tratamiento de las enfermedades de la deposición del amiloide, composiciones farmacéuticas que comprenden el anticuerpo, métodos y materiales para producir el anticuerpo y métodos para tratar la enfermedad de la deposición del amiloide usando el anticuerpo y la composición farmacéutica.
CONC2020/0000260A 2017-06-29 2020-01-13 Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide CO2020000260A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762526835P 2017-06-29 2017-06-29
PCT/US2018/039905 WO2019006062A1 (en) 2017-06-29 2018-06-28 CHIMERIC ANTIBODIES FOR THE TREATMENT OF AMYLOID DETECTION DISEASES

Publications (1)

Publication Number Publication Date
CO2020000260A2 true CO2020000260A2 (es) 2020-04-13

Family

ID=64743039

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0000260A CO2020000260A2 (es) 2017-06-29 2020-01-13 Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide

Country Status (13)

Country Link
US (2) US11530257B2 (es)
EP (1) EP3624842A4 (es)
JP (1) JP2020526191A (es)
KR (2) KR20230164223A (es)
CN (2) CN117924478A (es)
AU (1) AU2018290898B2 (es)
BR (1) BR112019028149A2 (es)
CA (1) CA3067597C (es)
CO (1) CO2020000260A2 (es)
IL (1) IL271488B1 (es)
MX (1) MX2019015914A (es)
RU (1) RU2746325C1 (es)
WO (1) WO2019006062A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
JP7337922B2 (ja) * 2018-10-31 2023-09-04 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク アミロイド沈着物を撮像するための方法および組成物
MX2022005850A (es) * 2019-11-15 2022-08-15 Univ Tennessee Res Found Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
CN117004700A (zh) * 2023-10-07 2023-11-07 北京爱博生生物技术有限公司 单克隆抗体可变区基因高通量测序的方法及其所用组合物与试剂盒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
DK1078005T3 (da) * 1998-05-21 2010-08-09 Univ Tennessee Res Foundation Fremgangsmåder til amyloidfjernelse ved anvendelse af anti-amyloidantistoffer
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
IL151378A0 (en) 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
KR20070040824A (ko) * 2004-07-30 2007-04-17 리나트 뉴로사이언스 코퍼레이션 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법
JP5033868B2 (ja) * 2006-03-23 2012-09-26 バイオアークティック ニューロサイエンス アーベー 改良型プロトフィブリル選択的抗体及びその使用
ATE451392T1 (de) * 2006-03-30 2009-12-15 Glaxo Group Ltd Gegen amyloid-beta peptid gerichtete antikörper
WO2008011348A2 (en) 2006-07-14 2008-01-24 Ac Immune S.A. Humanized antibody against amyloid beta
JP5500730B2 (ja) 2007-09-13 2014-05-21 デレネックス セラピューティクス アーゲー β−アミロイドペプチドに対するヒト化抗体
EP2730659A3 (en) * 2007-12-28 2016-01-13 Prothena Biosciences Limited Treatment and Prophylaxis of Amyloidosis
US8195594B1 (en) 2008-02-29 2012-06-05 Bryce thomas Methods and systems for generating medical reports
US20090297439A1 (en) 2008-06-02 2009-12-03 Metheresis Translational Research Sa, Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits
CN104023743B (zh) 2011-10-25 2017-05-03 普罗西纳治疗有限公司 抗体制剂和方法
WO2016032949A1 (en) * 2014-08-26 2016-03-03 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases

Also Published As

Publication number Publication date
RU2746325C1 (ru) 2021-04-12
US20200181246A1 (en) 2020-06-11
CA3067597A1 (en) 2019-01-03
US11530257B2 (en) 2022-12-20
CN117924478A (zh) 2024-04-26
IL271488A (en) 2020-02-27
AU2018290898B2 (en) 2021-03-11
US20230212273A1 (en) 2023-07-06
MX2019015914A (es) 2020-08-06
KR20230164223A (ko) 2023-12-01
EP3624842A4 (en) 2021-04-07
EP3624842A1 (en) 2020-03-25
BR112019028149A2 (pt) 2020-07-21
KR102607629B1 (ko) 2023-12-01
IL271488B1 (en) 2024-02-01
AU2018290898A1 (en) 2020-01-16
CA3067597C (en) 2023-03-21
JP2020526191A (ja) 2020-08-31
CN111093692A (zh) 2020-05-01
WO2019006062A1 (en) 2019-01-03
KR20200022479A (ko) 2020-03-03

Similar Documents

Publication Publication Date Title
CL2019000979A1 (es) Composiciones y anticuerpos anti-lag-3.
CO2020000260A2 (es) Anticuerpos quiméricos para el tratamiento de enfermedades de deposición del amiloide
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017013356A2 (es) Anticuerpos de factor xi
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
CO2019014286A2 (es) Bis-octahidrofenantreno carboxamidas y conjugados de proteína de las mismas
CL2021002637A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano y métodos para antagonizar cb1 (divisional de la solicitud no. 201602433)
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
AR101740A1 (es) Terapia de combinación y composiciones
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CO2019007686A2 (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo
BR112017012381A2 (pt) imunoterapia para doença angiogênica
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
BR112018013256A2 (pt) anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo